Then, based on the information of OS, DSS, and PFI, we performed subgroup analyses of prognosis, which demonstrated that survival rates of HCC samples with higher METTL18 expression was poor in T stages 3–4, N0, M0, and G3−4 subgroups of OS and pathologic stage III−IV subgroup of OS (Figures 5E–I). Here, METTL18 is linked to hepatocellular carcinoma.